Perrigo CoMEX:PRGON 44 Days Payable is 64.40 as of Mar. 2026, which is 3% above its 10-year median of 62.49. GuruFocus rates MEX:PRGON with a GF Score™ of 44/100 and a GF Value™ of MXN1,468.70. The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Perrigo Co ranks worse than 66.2% on this metric.
Perrigo Co's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN8,192 Mil. Perrigo Co's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN11,608 Mil.
Hence, Perrigo Co's Days Payable for the
three
months ended in Mar. 2026 was 64.40.
The historical rank and industry rank for Perrigo Co's Days Payable or its related term are showing as below:
MEX:PRGON'
s Days Payable Range Over the Past 10 Years
Min: 56.71 Med: 62.49 Max: 74.54
Current: 62.9
During the past 13 years, Perrigo Co's highest Days Payable was 74.54. The lowest was 56.71. And the median was 62.49.
MEX:PRGON's Days Payable is ranked worse than 66.2% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs MEX:PRGON: 62.90
Perrigo Co's Days Payable
declined
from Mar. 2025 (70.52) to Mar. 2026 (64.40).
It may suggest that Perrigo Coaccelerated paying its suppliers.
Perrigo Co Days Payable Related Terms
Perrigo Co Days Payable Historical Data
* Premium members only.
The historical data trend for Perrigo Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRGON vs AMLX, HROW, ANIP: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Perrigo Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Perrigo Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (MEX:PRGON) has a Days Payable of 64.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Perrigo Co and its competitors. This is near median its historical median of 62.49. Over the past decade, Perrigo Co's Days Payable has ranged from 56.71 to 74.54. According to the industry distribution chart, Perrigo Co ranks #611 out of 923 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Perrigo Co's Days Payable too high?
Perrigo Co's current Days Payable of 64.40 is near median its 10-year median of 62.49. Over the past 10 years, this metric has ranged from a low of 56.71 to a high of 74.54. The Drug Manufacturers industry median Days Payable is 90.98. Perrigo Co's value of 64.40 is 29.2% below this industry median. Based on the distribution chart, Perrigo Co ranks #611 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Perrigo Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's Days Payable compare to AMLX and HROW?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #611 out of 923 companies for Days Payable. This places Perrigo Co in the lower half of its industry. The industry median Days Payable is 90.98. Perrigo Co's value of 64.40 is 29.2% below this benchmark. Historically, Perrigo Co's own Days Payable has ranged from 56.71 to 74.54 over the past decade. While the company's 10-year median is 62.49 vs. the industry median of 90.98, Perrigo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current Days Payable of 64.40 is 29.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Perrigo Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current Days Payable is 64.40, which is near median its own 10-year median of 62.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Perrigo Co (MEX:PRGON) has a current Days Payable of 64.40. The stock's GF Value™ is MXN1,468.70, compared to a current price of MXN557.52 — trading 62% below its estimated fair value. The current Days Payable is 64.40, which is near median its 10-year median of 62.49 and 29.2% below the Drug Manufacturers industry median of 90.98. Perrigo Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Perrigo Co (MEX:PRGON), the current Days Payable is 64.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (MEX:PRGON) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of MXN557.52 is trading 62% below its estimated GF Value™ of MXN1,468.70.
Key valuation signals for MEX:PRGON:
Days Payable: 64.40 (near median its 10-year median of 62.49)
GF Value™: MXN1,468.70 vs. price of MXN557.52 (62% below fair value)
Industry Position: 29.2% below the Drug Manufacturers median (#611 of 923)
No single metric tells the full story. See the MEX:PRGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
44GF Score
Get the complete analysis for MEX:PRGON
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRGON has been successfully added to your 
